NCM · Biotechnology

MoonLake Immunotherapeutics (MLTX) Stock

$10.82 +2.27% NCM: MLTX Healthcare

Valuation

MetricValue
Price$10.82
Market Cap$910.13M
P/E Ratio-2.96
P/B Ratio1.97
P/S Ratio0.00
EPS (TTM)$-3.53
52-Week High$23.29
52-Week Low$8.18
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-82.68%
ROA-45.94%
ROCE-50.77%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.24
Current Ratio9.38

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-54.0M$-65.0M$-54.0M$-143.0M$-245.0M
Net Profit$-54.0M$-50.0M$-36.0M$-119.0M$-227.0M
EPS$-1.45$-1.70$-0.73$-1.89$-3.53
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$10.0M$77.0M$527.0M$478.0M$424.0M
Total Liabilities$21.0M$8.0M$13.0M$25.0M$120.0M
Cash$8.0M$40.0M$451.0M$180.0M$335.0M
Borrowings$15.0M$0$4.0M$3.0M$76.0M

Latest News

SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears Stocktwits · Jul 13, 2026 MoonLake Immunotherapeutics' CFO Sells 39K Shares Motley Fool · Jul 3, 2026 MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa Insider Monkey · Jun 30, 2026 How Investors May Respond To MoonLake Immunotherapeutics (MLTX) VELA Data And Upsized Follow-On Offering Simply Wall St. · Jun 25, 2026 Why MoonLake Immunotherapeutics Stock Wilted on Wednesday Motley Fool · Jun 25, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-35.0M$-56.0M$-43.0M$-117.0M$-196.0M
Investing Cash Flow$0$-32.0M$-25.0M$-206.0M$203.0M
Financing Cash Flow$0$135.0M$-3.0M$-1.0M$0
Net Cash Flow$7.0M$31.0M$412.0M$-271.0M$154.0M
Free Cash Flow$-35.0M$-56.0M$-43.0M$-117.0M$-196.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.09
EV / EBITDA-2.33
FCF Yield-23.46%
Quick Ratio12.56
Interest Coverage-26.58
Return 1Y-65.27%
Return 3Y-64.13%
Return 5Y93.60%

Ownership

Insiders Held8.42%
Institutions Held78.26%
Institutions Float Held85.46%
Institutional HolderSharesReport Date
BVF Inc.16,001,2842026-03-31
Deep Track Capital, Lp6,408,8632026-03-31
Cormorant Asset Management, LP4,480,4332026-03-31
Janus Henderson Group PLC3,451,6282026-03-31
Shaw D.E. & Co., Inc.2,390,6612026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACRSAclaris Therapeutics, Inc. $3.83 +1.06% -8.88 $534.91M 0.00%
ALMSAlumis Inc. $7.16 +2.73% -1.80 $883.77M 0.00%
ANABAnaptysBio, Inc. $45.95 -0.56% 7.19 $1.36B 0.00%
ATTOAttovia Therapeutics, Inc. $16.21 -0.61% -23.81 $697.52M 0.00%
CNTBConnect Biopharma Holdings Limited $0.87 -1.21% -1.05 $54.78M 0.00%

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is led by CEO Jorge Santos da Silva, employs 100 people, headquartered in CH, publicly traded since 2020.

MoonLake Immunotherapeutics (MLTX) stock trades at $10.82 with a market capitalization of $910.13M. The stock is valued at a price-to-earnings (P/E) ratio of -2.96, price-to-book of 1.97, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $8.18 and $23.29, and currently trades 53.5% below its 52-week high.

On profitability, MoonLake Immunotherapeutics generates a return on equity (ROE) of -82.68%, return on capital employed of -50.77%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides